Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.

The oncologist - 1 Jan 2012

Ou Sai-Hong Ignatius, Bartlett Cynthia Huang, Mino-Kenudson Mari, Cui Jean, Iafrate A John

Abstract excerpt

Crizotinib, an ALK/MET/ROS1 inhibitor, was approved by the U.S. Food and Drug Administration for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) in August 2011, merely 4 years after the first publication of ALK-rearranged NSCLC. The crizotinib approval was accompanied by the simultaneous approval of an ALK companion diagnostic fluorescent in situ hybridization assay...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Crizotinib

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Interactions

Share to Gene Rearrangement

Share to Proto-Oncogene Proteins c-met

Share to Pyrazoles

Share to Pyridines

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 22989574
DOI: 10.1634/theoncologist.2012-0311
PMCID: PMC3500356

Genes

ALK
ROS1
MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.PMID 22989574Read ↗

Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung CancerSemantic proximity Read ↗

Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitorsSemantic proximity Read ↗

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to DateSemantic proximity Read ↗

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted TherapiesSemantic proximity Read ↗

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.Semantic proximity Read ↗

Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant AlterationsSemantic proximity Read ↗

ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.Semantic proximity Read ↗

Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to CrizotinibSemantic proximity Read ↗

Importance of ROS1 fene fusions in non-small cell lung cancerSemantic proximity Read ↗

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK RearrangementsSemantic proximity Read ↗

<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung CancersSemantic proximity Read ↗

Molecular Changes Associated with Acquired Resistance to Crizotinib in <i>ROS1</i> -Rearranged Non–Small Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.